Iranian Journal of Toxicology
مجله سم شناسی و مسمومیتهای ایران
IJT
Medical Sciences
http://ijt.arakmu.ac.ir
1
admin
2008-2967
2251-9459
8
10.61186/ijt
14
8888
13
en
jalali
1400
10
1
gregorian
2022
1
1
16
1
online
1
fulltext
en
Transurethral Intraprostatic Botulinum Toxin-a Injection in Patients with Benign Prostatic Hyperplasia: A Case Series and Literature Review
تخصصي
Special
پژوهشي
Research
<strong>Background</strong>: We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH).<br>
<strong>Methods</strong>: Fifteen patients were included in this study. The drug (BTA; 150 IU) was reconstituted in 20 mL of 0.9% saline before administration to the patients. After providing urethral anesthesia, 20 intraurethral injections were made to lateral lobes of the prostate, 10 injections in each lobe. Follow-up visits were planned 3 and 12 months after the intervention. Pre- and post-interventional IPSS, Prostate-Specific Antigen (PSA), Prostate Volume (PV), Post-Void Residue (PVR), and maximum urinary flow rate (Qmax) compared via paired t-test. Finally, we reviewed the Pubmed database to provide a more precise conclusion.<br>
<strong>Results</strong>: The Mean±SD age of patients was 69±8.24 years, and the mean IPSS score decreased significantly from 24.3±3.3 to 14.6±3.7 (p<0.001) and 16.86±3.06 (p<0.009) on the 3rd and 12th months, respectively. The Mean±SD PSA, PVR, Qmax, and PV were 3.26±1.38, 82.33±35.55, 8.56±1.76, and 47.86±8.93, respectively at baseline. These factors significantly improved to 2.72±1.33 (P<0.000), 71.33±30.55 (p<0.000), 9.5±1.33 (p<0.011), and 42.86± 6.04 (p<0.000), respectively, on the 12th month follow-up.<br>
<strong>Conclusion</strong>: Although the overall results support the efficacy of BTA for BPH, the best route of administration, the most effective dose, the optimal number, and the volume of injections need further investigations. The probable placebo effect and underlying medical conditions (e.g., insulin resistance) should be considered as the confounding factors.<br>
Benign prostatic hyperplasia, Benign prostatic hypertrophy, Botox, Onabotulinumtoxin-A, Botulinum toxin A
9
16
http://ijt.arakmu.ac.ir/browse.php?a_code=A-10-851-1&slc_lang=en&sid=1
Mahmoud
Tavakkoli
tavakkolim@mums.ac.ir
100319475328460012569
100319475328460012569
No
Department of Urology, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamidreza
Ghorbani
ghorbanihr@mums.ac.ir
100319475328460012570
100319475328460012570
No
Department of Urology, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amin
Nobahar
Med_student82@yahoo.com
100319475328460012571
100319475328460012571
No
Department of Urology, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam
Emadzadeh
emadzadehm@mums.ac.ir
100319475328460012572
100319475328460012572
No
Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Atena
Aghaee
aghaeeat@mums.ac.ir
100319475328460012573
100319475328460012573
No
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahdi
Mottaghi
mmottaghi.3000@gmail.com
100319475328460012574
100319475328460012574
No
Department of Urology, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Salman
Soltani
soltanis@mums.ac.ir
100319475328460012575
100319475328460012575
Yes
Department of Urology, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.